Progenics Pharmaceuticals and Wyeth achieved positive results from a three-month open-label extension study of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients with advanced illness. Eighty-two OIC patients completed a placebo-controlled Phase III study (MNTX 302) and participated in the three-month open-label extension study of subcutaneous methylnaltrexone. The goal of the extension study was to obtain efficacy and safety data on subcutaneous m...